Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 1.00 |
| ▸ | FYN | P06241 | 10/20 | 0.84 |
| ▸ | YES1 | P07947 | 10/20 | 0.84 |
| ▸ | KDR | P35968 | 10/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.84 |
| ▸ | LCK | P06239 | 9/20 | 0.84 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797291 | 0.93 | SRC (0.86) | SRCFYNYES1KDRPDGFRB | |
| SCHEMBL6618462 | 0.93 | SRC (1.00) | SRCFYNYES1KDRPDGFRB | |
| SCHEMBL6613019 | 0.92 | SRC (1.00) | SRCFYNYES1KDRPDGFRB | |
| SCHEMBL6613334 | 0.92 | SRC (1.00) | SRCFYNYES1KDRPDGFRB | |
| SCHEMBL6619124 | 0.91 | SRC (1.00) | SRCFYNYES1KDRPDGFRB | |
| SCHEMBL6613582 | 0.91 | SRC (1.00) | SRCFYNYES1KDRPDGFRB | |
| SCHEMBL6803809 | 0.90 | SRC (1.00) | SRCFYNYES1KDRPDGFRB | |
| SCHEMBL6805177 | 0.89 | SRC (0.87) | SRCFYNYES1KDRPDGFRB | |
| SCHEMBL6692770 | 0.89 | SRC (0.98) | SRCFYNYES1KDRPDGFRB | |
| SCHEMBL6613279 | 0.86 | SRC (0.81) | SRCFYNYES1KDRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266855-A1 | 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6777417-B2 | ANTICANCER AGENTS | SUGEN, INC. | 2004-08-17 | — | — | US | disclosed |
| EP-1436259-A1 | 3-(4,5,6,7-TETRAHYDROINDOL-2-YLMETHYLIDIENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | Liang, Congxin (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030119819-A1 | 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2003022815-A1 | 3-(4,5,6,7-TETRAHYDROINDOL-2-YLMETHYLIDIENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266855-A1 | 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors | SRC, LCK, MAP3K20 | SRC 1/4885FYN 15/4885YES1 287/4885 |
| US-20030119819-A1 | 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors | SRC, LCK, MAP3K20 | SRC 1/4885FYN 26/4885YES1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.